PGT-A in Thailand: Cost, Top Specialists & Hospitals

PGT-A screens IVF embryos for aneuploidy — having too many or too few chromosomes — before transfer. A tiny biopsy from the outer layer of the blastocyst is analysed using next-generation sequencing to confirm the correct chromosome count across all 23 pairs. Transferring euploid (chromosomally normal) embryos improves implantation rates to 60–70% and significantly reduces miscarriage risk.

The biopsy is taken from the trophectoderm — the outer cell layer that becomes the placenta — not from the inner cell mass that develops into the baby. This means the embryo itself is not harmed. Results take one to two weeks, during which embryos are vitrified. A euploid embryo is then selected for transfer in a subsequent FET cycle.

PGT-A in Thailand costs between $2,000 and $3,600 for testing of up to eight embryos. Additional per-embryo fees apply above this number. The cost covers genetic counselling, the biopsy procedure, NGS analysis, results consultation, and a written report with recommendations.

The PGT-A fee includes genetic counselling before testing, the embryo biopsy performed by the embryology team, the genetic analysis using next-generation sequencing, a results consultation, and a comprehensive written report. If you have more than eight embryos to test, additional per-embryo fees apply. The IVF cycle itself is priced separately.

The number of embryos tested is the main variable. The base fee typically covers up to eight embryos, with additional charges per embryo above that threshold. If PGT-M (single-gene testing) is combined with PGT-A on the same biopsy, additional fees apply for the PGT-M component. The IVF cycle cost, medication, and embryo freezing are all separate line items.

Pricing varies by the complexity and scope of the procedure. Typical ranges at our partner hospitals in Thailand:

• PGT-A for up to 4 embryos: $2,000–$2,500 — biopsy and chromosomal screening of a small embryo cohort
• PGT-A for 5–8 embryos: $2,500–$3,000 — mid-range cohort with per-embryo cost reduction
• PGT-A for 9 or more embryos: $3,000–$3,600 — large cohort testing at the lowest per-embryo rate

Exact pricing is confirmed after your consultation and treatment plan are finalised.

PGT-A in Thailand costs 50–70% less than equivalent testing in the US ($5,000–$9,000), Australia (A$4,400–A$8,000), and UK (£4,000–£7,000). Given the significant impact PGT-A has on per-transfer success rates and miscarriage reduction, the lower Thai pricing makes it a practical addition to any IVF cycle rather than an expensive upgrade.

No additional stay is needed beyond your IVF cycle. The biopsy happens during the standard embryo culture period. Results take one to two weeks, during which you can return home. You will return for a frozen embryo transfer — a separate visit of five to seven days — once results confirm a euploid embryo is available.

This is a possibility, particularly for women over 40 where aneuploidy rates are higher. If all tested embryos are aneuploid, options include another IVF cycle to produce more embryos, using donor eggs, or other treatment pathways. Knowing the result in advance prevents you from transferring embryos with very low implantation potential — saving time, money, and the emotional toll of an unsuccessful transfer.

PGT-A is most beneficial for women over 35, where aneuploidy rates increase significantly. For younger patients, the majority of embryos are likely euploid, so the added value of testing is smaller. However, PGT-A may still be worthwhile if you have a history of miscarriage, repeated transfer failure, or if you want to maximise the chance of success from a single transfer — particularly relevant for international patients who want to avoid multiple trips.

Yes. PGT-A is performed at licensed fertility clinics using the same biopsy equipment and NGS platforms found in top genetics laboratories worldwide. Our partner clinics employ experienced embryologists with documented biopsy proficiency and work with accredited genetics labs for analysis. Quality-control measures meet international standards.

PGT-A has high accuracy for detecting whole-chromosome aneuploidy — the most common cause of implantation failure and early miscarriage. However, it is not perfect. False positives (an embryo classified as aneuploid that is actually normal) and false negatives (the opposite) can occur, though both are rare. Mosaicism — where a biopsy sample contains a mix of normal and abnormal cells — adds complexity. These limitations are discussed in your genetic counselling session.

A mosaic embryo contains a mixture of chromosomally normal and abnormal cells. Mosaicism is detected in roughly 10–20% of biopsied embryos. Low-level mosaic embryos may still be considered for transfer in some circumstances, as a proportion can self-correct during development. The decision is made with genetic counselling, weighing the level and type of mosaicism against the alternative options available to you.

Our partner clinics have in-house or closely partnered genetics laboratories equipped with NGS platforms for PGT-A analysis. Their embryologists perform trophectoderm biopsies routinely with documented low damage rates. The combination of experienced biopsy technique and reliable analysis produces consistent, actionable results.

PGT-A results require expert interpretation — particularly mosaic results. Our partner clinics provide genetic counselling from qualified professionals who explain the clinical significance of each result and help you make informed decisions. This is not a generic lab report — it is a personalised consultation.

Ask about the clinic's biopsy damage rate (should be under 1%). Confirm they use NGS technology, not older aCGH platforms. Check whether genetic counselling is included in the PGT-A package. Ask about turnaround time — one to two weeks is standard. And confirm the clinic handles mosaic results with nuance rather than blanket rejection of all mosaic embryos.

Studies consistently show that transferring a PGT-A-screened euploid embryo improves implantation rates to 60–70% (versus 40–50% without testing) and significantly reduces miscarriage risk. The benefit is greatest for women over 35, where the proportion of aneuploid embryos increases with age. For women over 40, more than half of embryos may be aneuploid — without testing, these would be transferred with very low success probability.

PGT-A screens for chromosome number, not single-gene disorders (that requires PGT-M). It does not assess embryo quality in terms of mitochondrial function, metabolic activity, or other developmental factors. A euploid embryo still needs a receptive uterine environment and correct transfer timing to implant. PGT-A improves the odds — it does not guarantee success.

The biopsy is performed on day five or six of embryo culture — within your standard IVF stay. Embryos are vitrified immediately after biopsy. You can return home while results are processed over one to two weeks. Once results confirm a euploid embryo, you return for a frozen embryo transfer — a separate visit of five to seven days.

PGT-A adds cost but can save money overall by reducing the number of unsuccessful transfers. It is most clearly beneficial for women over 35, those with recurrent miscarriage, and those who have experienced repeated implantation failure. For younger patients with multiple good-quality embryos, the added value is smaller — but the confidence of knowing you are transferring a chromosomally normal embryo may still be worthwhile.

If you carry a known genetic condition, PGT-M (testing for a specific gene) can be performed on the same biopsy as PGT-A. This screens embryos for both chromosomal abnormalities and the specific inherited condition simultaneously. The combined approach gives you the most comprehensive information about each embryo before transfer.